Cortagen vs Epithalon

Brain cortex-derived tetrapeptide that modulates gene expression in neural and cardiac tissue through chromatin regulatory mechanisms; microarray analysis demonstrates broad transcriptional effects following administration.

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) classified as a Khavinson-class bioregulator derived from cerebral cortex tissue, investigated for gene expression regulatory effects in neural and cardiac tissue. As a Khavinson-class bioregulator, cortagen is proposed to modulate transcriptional activity in aging target tissue by interacting with gene regulatory elements; microarray analysis of cardiac gene expression following cortagen administration has demonstrated broad effects on transcriptional profiles across multiple functional gene categories, suggesting tissue-regulatory activity beyond its cortical tissue origin. Published research on Khavinson-class peptides has further characterized the systematic gene expression regulatory potential of short bioregulator peptides across tissue types, providing the mechanistic context within which cortagen's transcriptional effects are interpreted. Cortagen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical studies with no independent clinical trials published in Western-indexed journals. Cortagen benefits investigated in preclinical research include neuroprotective effects in neural tissue, cardiovascular gene expression modulation, and support for vascular wall integrity in aged animal models. As a brain cortex-derived Khavinson bioregulator, cortagen is proposed to regulate transcription in neural and cardiac tissue through chromatin-level mechanisms, potentially preserving tissue-specific gene expression patterns that decline with aging. Research interest encompasses cortagen's role in neurological aging, post-ischemic brain tissue recovery in preclinical models, and combined bioregulator protocols that pair cortagen with cardiovascular and metabolic peptides for comprehensive longevity applications. Cortagen is a research compound with no regulatory approval in any jurisdiction; evidence is limited to preclinical studies and Russian clinical research literature, with no independent randomized trials published in Western peer-reviewed journals.

Epithalon is believed to activate telomerase, the enzyme responsible for maintaining telomere length, with several in vitro and animal studies reporting telomere elongation. It also appears to regulate the expression of p53 and other cell-cycle control genes, modulate the hypothalamic-pituitary axis via pineal gland activity, and upregulate antioxidant defences including superoxide dismutase and catalase.

Epithalon (Ala-Glu-Asp-Gly; AEDG peptide) is a synthetic tetrapeptide developed by Vladimir Khavinson as a more stable analog of the native pineal tetrapeptide epithalamin, proposed to restore physiological circadian rhythm regulation and telomerase activity in aging cells, and to exert broad anti-aging effects through epigenetic gene expression modulation in pineal and other tissues. Epithalon is proposed to activate telomerase and modulate telomere maintenance in aging somatic cells, normalize melatonin production and the neuroendocrine-immune axis, and restore physiological parameters that decline with aging; in vitro studies and preclinical animal models provide mechanistic support for these effects. Published human studies from the Khavinson group include a controlled clinical trial demonstrating epithalon's effects on retinal function in retinitis pigmentosa patients and observational data showing melatonin rhythm normalization in elderly subjects, representing the strongest indexed clinical evidence specifically for epithalon; both studies are formally indexed in PubMed. Epithalon has no FDA approval and no approved indication in any Western jurisdiction; published clinical evidence derives from a single research group without external independent replication by standard Western trial methodology, and while the mechanistic and observational research is indexed in peer-reviewed journals, the evidence base does not meet the threshold for established efficacy in any recognized clinical condition. Epithalon dosage protocols: no human clinical trial has established a standardized dosing regimen for epithalon. The published Khavinson clinical research does not report specific dose-response data in a format translatable to general dosing guidance. No dose-ranging clinical trial has been conducted for epithalon; research community protocols are derived from the animal research and Khavinson group bioregulator framework rather than validated human studies. Intranasal delivery has also been explored due to direct CNS access via the olfactory pathway. Epithalon is a research compound with no approved clinical dosing guidelines in any jurisdiction.